Moreover, even for the exclusively EGFR-mutant advanced NSCLC patients, the median progression-free survival (PFS) was only 9∼13 months for those who received the first-line EGFR-TKI therapy and developed secondary resistance [1, 2]. Here, EGFR is linked to non-small cell lung carcinoma.